# Optimization for Regorafenib in HCC

> **NCT04476329** · PHASE2 · TERMINATED · sponsor: **SC Liver Research Consortium, LLC** · enrollment: 7 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Regorafenib 40 MG

## Key facts

- **NCT ID:** NCT04476329
- **Lead sponsor:** SC Liver Research Consortium, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-12-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476329, "Optimization for Regorafenib in HCC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04476329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*